> top > docs > PubMed:3922920 > annotations

PubMed:3922920 JSONTXT

Annnotations TAB JSON ListView MergeView

spacy-test

Id Subject Object Predicate Lexical cue
spaCy_T0 0-13 JJ denotes Immunoblastic
spaCy_T1 14-22 NN denotes lymphoma
spaCy_T2 23-26 CC denotes and
spaCy_T3 27-33 JJ denotes thymic
spaCy_T4 34-44 JJ denotes epithelial
spaCy_T5 45-56 NN denotes hyperplasia
spaCy_T6 57-59 IN denotes in
spaCy_T7 60-78 JJ denotes angioimmunoblastic
spaCy_T8 79-94 NN denotes lymphadenopathy
spaCy_T9 95-104 VBG denotes following
spaCy_T10 105-109 NN denotes gold
spaCy_T11 110-117 NN denotes therapy
spaCy_T12 117-118 . denotes .
spaCy_T13 119-120 DT denotes A
spaCy_T14 121-132 JJ denotes 62-year-old
spaCy_T15 133-138 NN denotes woman
spaCy_T16 139-143 IN denotes with
spaCy_T17 144-160 JJ denotes well-established
spaCy_T18 161-174 NN denotes polyarthritis
spaCy_T19 175-184 VBD denotes developed
spaCy_T20 185-203 JJ denotes angioimmunoblastic
spaCy_T21 204-219 NN denotes lymphadenopathy
spaCy_T22 220-221 -LRB- denotes (
spaCy_T23 221-225 NNP denotes AILD
spaCy_T24 225-226 -RRB- denotes )
spaCy_T25 227-233 IN denotes during
spaCy_T26 234-238 NN denotes gold
spaCy_T27 239-246 NN denotes therapy
spaCy_T28 246-247 . denotes .
spaCy_T29 248-251 PRP denotes She
spaCy_T30 252-264 RB denotes subsequently
spaCy_T31 265-274 VBD denotes developed
spaCy_T32 275-277 DT denotes an
spaCy_T33 278-291 JJ denotes immunoblastic
spaCy_T34 292-300 NN denotes lymphoma
spaCy_T35 301-306 WDT denotes which
spaCy_T36 307-313 VBD denotes showed
spaCy_T37 314-327 NN denotes monoclonality
spaCy_T38 328-329 -LRB- denotes (
spaCy_T39 329-332 NNP denotes IgA
spaCy_T40 332-333 , denotes ,
spaCy_T41 334-340 NN denotes lambda
spaCy_T42 340-341 -RRB- denotes )
spaCy_T43 342-344 IN denotes by
spaCy_T44 345-361 NN denotes immunoperoxidase
spaCy_T45 362-372 NNS denotes techniques
spaCy_T46 372-373 . denotes .
spaCy_T47 374-379 EX denotes There
spaCy_T48 380-383 VBD denotes was
spaCy_T49 384-385 DT denotes a
spaCy_T50 386-396 JJ denotes tumor-like
spaCy_T51 397-408 NN denotes enlargement
spaCy_T52 409-411 IN denotes of
spaCy_T53 412-415 DT denotes the
spaCy_T54 416-422 NN denotes thymus
spaCy_T55 423-428 NN denotes gland
spaCy_T56 429-432 JJ denotes due
spaCy_T57 433-435 TO denotes to
spaCy_T58 436-447 NN denotes involvement
spaCy_T59 448-450 IN denotes by
spaCy_T60 451-455 NNP denotes AILD
spaCy_T61 455-456 , denotes ,
spaCy_T62 457-461 IN denotes with
spaCy_T63 462-471 JJ denotes secondary
spaCy_T64 472-485 NN denotes proliferation
spaCy_T65 486-488 IN denotes of
spaCy_T66 489-495 JJ denotes thymic
spaCy_T67 496-506 NN denotes epithelium
spaCy_T68 506-507 . denotes .
spaCy_T69 508-511 DT denotes The
spaCy_T70 512-519 NN denotes finding
spaCy_T71 520-522 IN denotes of
spaCy_T72 523-529 JJ denotes thymic
spaCy_T73 530-541 NN denotes involvement
spaCy_T74 541-542 , denotes ,
spaCy_T75 543-548 WDT denotes which
spaCy_T76 549-552 VBZ denotes has
spaCy_T77 553-556 RB denotes not
spaCy_T78 557-561 VBN denotes been
spaCy_T79 562-571 VBN denotes described
spaCy_T80 572-582 RB denotes previously
spaCy_T81 583-585 IN denotes in
spaCy_T82 586-590 NNP denotes AILD
spaCy_T83 590-591 , denotes ,
spaCy_T84 592-597 MD denotes might
spaCy_T85 598-600 VB denotes be
spaCy_T86 601-604 CD denotes one
spaCy_T87 605-607 IN denotes of
spaCy_T88 608-611 DT denotes the
spaCy_T89 612-626 NNS denotes manifestations
spaCy_T90 627-637 VBG denotes reflecting
spaCy_T91 638-639 DT denotes a
spaCy_T92 640-651 NN denotes disturbance
spaCy_T93 652-654 IN denotes of
spaCy_T94 655-658 DT denotes the
spaCy_T95 659-665 JJ denotes immune
spaCy_T96 666-672 NN denotes system
spaCy_T97 673-675 IN denotes in
spaCy_T98 676-680 DT denotes this
spaCy_T99 681-688 NN denotes disease
spaCy_T100 688-689 . denotes .
spaCy_R52 spaCy_T52 spaCy_T51 prep of,enlargement
spaCy_R53 spaCy_T53 spaCy_T55 det the,gland
spaCy_R0 spaCy_T0 spaCy_T1 amod Immunoblastic,lymphoma
spaCy_R1 spaCy_T1 spaCy_T1 ROOT lymphoma,lymphoma
spaCy_R2 spaCy_T2 spaCy_T1 cc and,lymphoma
spaCy_R3 spaCy_T3 spaCy_T5 amod thymic,hyperplasia
spaCy_R4 spaCy_T4 spaCy_T5 amod epithelial,hyperplasia
spaCy_R5 spaCy_T5 spaCy_T1 conj hyperplasia,lymphoma
spaCy_R6 spaCy_T6 spaCy_T5 prep in,hyperplasia
spaCy_R7 spaCy_T7 spaCy_T8 amod angioimmunoblastic,lymphadenopathy
spaCy_R8 spaCy_T8 spaCy_T6 pobj lymphadenopathy,in
spaCy_R9 spaCy_T9 spaCy_T9 ROOT following,following
spaCy_R10 spaCy_T10 spaCy_T11 compound gold,therapy
spaCy_R11 spaCy_T11 spaCy_T9 dobj therapy,following
spaCy_R12 spaCy_T12 spaCy_T9 punct .,following
spaCy_R13 spaCy_T13 spaCy_T15 det A,woman
spaCy_R14 spaCy_T14 spaCy_T15 amod 62-year-old,woman
spaCy_R15 spaCy_T15 spaCy_T19 nsubj woman,developed
spaCy_R16 spaCy_T16 spaCy_T15 prep with,woman
spaCy_R17 spaCy_T17 spaCy_T18 amod well-established,polyarthritis
spaCy_R18 spaCy_T18 spaCy_T16 pobj polyarthritis,with
spaCy_R19 spaCy_T19 spaCy_T19 ROOT developed,developed
spaCy_R20 spaCy_T20 spaCy_T21 amod angioimmunoblastic,lymphadenopathy
spaCy_R21 spaCy_T21 spaCy_T19 dobj lymphadenopathy,developed
spaCy_R22 spaCy_T22 spaCy_T21 punct (,lymphadenopathy
spaCy_R23 spaCy_T23 spaCy_T21 appos AILD,lymphadenopathy
spaCy_R24 spaCy_T24 spaCy_T21 punct ),lymphadenopathy
spaCy_R25 spaCy_T25 spaCy_T19 prep during,developed
spaCy_R26 spaCy_T26 spaCy_T27 compound gold,therapy
spaCy_R27 spaCy_T27 spaCy_T25 pobj therapy,during
spaCy_R28 spaCy_T28 spaCy_T19 punct .,developed
spaCy_R29 spaCy_T29 spaCy_T31 nsubj She,developed
spaCy_R30 spaCy_T30 spaCy_T31 advmod subsequently,developed
spaCy_R31 spaCy_T31 spaCy_T31 ROOT developed,developed
spaCy_R32 spaCy_T32 spaCy_T34 det an,lymphoma
spaCy_R33 spaCy_T33 spaCy_T34 amod immunoblastic,lymphoma
spaCy_R34 spaCy_T34 spaCy_T31 dobj lymphoma,developed
spaCy_R35 spaCy_T35 spaCy_T36 nsubj which,showed
spaCy_R36 spaCy_T36 spaCy_T34 relcl showed,lymphoma
spaCy_R37 spaCy_T37 spaCy_T36 dobj monoclonality,showed
spaCy_R38 spaCy_T38 spaCy_T39 punct (,IgA
spaCy_R39 spaCy_T39 spaCy_T37 appos IgA,monoclonality
spaCy_R40 spaCy_T40 spaCy_T39 punct ",",IgA
spaCy_R41 spaCy_T41 spaCy_T39 appos lambda,IgA
spaCy_R42 spaCy_T42 spaCy_T39 punct ),IgA
spaCy_R43 spaCy_T43 spaCy_T36 prep by,showed
spaCy_R44 spaCy_T44 spaCy_T45 compound immunoperoxidase,techniques
spaCy_R45 spaCy_T45 spaCy_T43 pobj techniques,by
spaCy_R46 spaCy_T46 spaCy_T31 punct .,developed
spaCy_R47 spaCy_T47 spaCy_T48 expl There,was
spaCy_R48 spaCy_T48 spaCy_T48 ROOT was,was
spaCy_R49 spaCy_T49 spaCy_T51 det a,enlargement
spaCy_R50 spaCy_T50 spaCy_T51 amod tumor-like,enlargement
spaCy_R51 spaCy_T51 spaCy_T48 attr enlargement,was
spaCy_R54 spaCy_T54 spaCy_T55 compound thymus,gland
spaCy_R55 spaCy_T55 spaCy_T52 pobj gland,of
spaCy_R56 spaCy_T56 spaCy_T51 amod due,enlargement
spaCy_R57 spaCy_T57 spaCy_T58 aux to,involvement
spaCy_R58 spaCy_T58 spaCy_T56 xcomp involvement,due
spaCy_R59 spaCy_T59 spaCy_T58 prep by,involvement
spaCy_R60 spaCy_T60 spaCy_T59 pobj AILD,by
spaCy_R61 spaCy_T61 spaCy_T60 punct ",",AILD
spaCy_R62 spaCy_T62 spaCy_T58 prep with,involvement
spaCy_R63 spaCy_T63 spaCy_T64 amod secondary,proliferation
spaCy_R64 spaCy_T64 spaCy_T62 pobj proliferation,with
spaCy_R65 spaCy_T65 spaCy_T64 prep of,proliferation
spaCy_R66 spaCy_T66 spaCy_T67 amod thymic,epithelium
spaCy_R67 spaCy_T67 spaCy_T65 pobj epithelium,of
spaCy_R68 spaCy_T68 spaCy_T48 punct .,was
spaCy_R69 spaCy_T69 spaCy_T70 det The,finding
spaCy_R70 spaCy_T70 spaCy_T85 nsubj finding,be
spaCy_R71 spaCy_T71 spaCy_T70 prep of,finding
spaCy_R72 spaCy_T72 spaCy_T73 amod thymic,involvement
spaCy_R73 spaCy_T73 spaCy_T71 pobj involvement,of
spaCy_R74 spaCy_T74 spaCy_T73 punct ",",involvement
spaCy_R75 spaCy_T75 spaCy_T79 nsubjpass which,described
spaCy_R76 spaCy_T76 spaCy_T79 aux has,described
spaCy_R77 spaCy_T77 spaCy_T79 neg not,described
spaCy_R78 spaCy_T78 spaCy_T79 auxpass been,described
spaCy_R79 spaCy_T79 spaCy_T73 relcl described,involvement
spaCy_R80 spaCy_T80 spaCy_T79 advmod previously,described
spaCy_R81 spaCy_T81 spaCy_T79 prep in,described
spaCy_R82 spaCy_T82 spaCy_T81 pobj AILD,in
spaCy_R83 spaCy_T83 spaCy_T85 punct ",",be
spaCy_R84 spaCy_T84 spaCy_T85 aux might,be
spaCy_R85 spaCy_T85 spaCy_T85 ROOT be,be
spaCy_R86 spaCy_T86 spaCy_T85 attr one,be
spaCy_R87 spaCy_T87 spaCy_T86 prep of,one
spaCy_R88 spaCy_T88 spaCy_T89 det the,manifestations
spaCy_R89 spaCy_T89 spaCy_T87 pobj manifestations,of
spaCy_R90 spaCy_T90 spaCy_T89 acl reflecting,manifestations
spaCy_R91 spaCy_T91 spaCy_T92 det a,disturbance
spaCy_R92 spaCy_T92 spaCy_T90 dobj disturbance,reflecting
spaCy_R93 spaCy_T93 spaCy_T92 prep of,disturbance
spaCy_R94 spaCy_T94 spaCy_T96 det the,system
spaCy_R95 spaCy_T95 spaCy_T96 amod immune,system
spaCy_R96 spaCy_T96 spaCy_T93 pobj system,of
spaCy_R97 spaCy_T97 spaCy_T92 prep in,disturbance
spaCy_R98 spaCy_T98 spaCy_T99 det this,disease
spaCy_R99 spaCy_T99 spaCy_T97 pobj disease,in
spaCy_R100 spaCy_T100 spaCy_T85 punct .,be

PubCasesHPO

Id Subject Object Predicate Lexical cue
TI1 14-22 HP:0002665 denotes lymphoma
TI2 79-94 HP:0002716 denotes lymphadenopathy
AB1 204-219 HP:0002716 denotes lymphadenopathy
AB2 292-300 HP:0002665 denotes lymphoma

oger-json-test

Id Subject Object Predicate Lexical cue
T1 14-22 D008223 denotes lymphoma
T2 45-56 D006965 denotes hyperplasia
T3 60-94 D007119 denotes angioimmunoblastic lymphadenopathy
T4 79-94 D000072281 denotes lymphadenopathy
T5 79-94 D008206 denotes lymphadenopathy
T6 105-109 CHEBI:29287 denotes gold
T7 105-109 CHEBI:30050 denotes gold
T8 161-174 D001168 denotes polyarthritis
T9 185-219 D007119 denotes angioimmunoblastic lymphadenopathy
T10 204-219 D000072281 denotes lymphadenopathy
T11 204-219 D008206 denotes lymphadenopathy
T12 234-238 CHEBI:29287 denotes gold
T13 234-238 CHEBI:30050 denotes gold
T14 292-300 D008223 denotes lymphoma
T15 329-332 PR:000001285 denotes IgA
T16 329-332 PR:P11911 denotes IgA
T17 329-332 D007070 denotes IgA
T18 386-391 D009369 denotes tumor
T19 681-688 D004194 denotes disease